{"id":11445,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2026-02-04T09:08:06","modified_gmt":"2026-02-04T09:08:06","slug":"hipertermija-qol-sapju-kontrole","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/lv\/hipertermija-qol-sapju-kontrole\/","title":{"rendered":"Hipertermijas ietekme uz dz\u012bves kvalit\u0101ti (QoL): S\u0101pju mazin\u0101\u0161ana, noguruma samazin\u0101\u0161ana un adjuvanti imunolo\u0123iskie ieguvumi"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n{\n  \"@context\": \"https:\/\/schema.org\",\n  \"@graph\": [\n    {\n      \"@type\": \"MedicalWebPage\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/lv\/hipertermija-qol-sapju-kontrole\/#webpage\",\n      \"url\": \"https:\/\/andromedichyperthermia.com\/lv\/hipertermija-qol-sapju-kontrole\/\",\n      \"name\": \"Hipertermija un QoL v\u0113\u017ea apr\u016bp\u0113 | Andromedic\",\n      \"description\": \"Uz pier\u0101d\u012bjumiem balst\u012bta anal\u012bze par to, k\u0101 hipertermijas modalit\u0101te uzlabo dz\u012bves kvalit\u0101ti (QoL), mazinot s\u0101pes (A1 l\u012bme\u0146a pier\u0101d\u012bjumi) un nogurumu.\",\n      \"isPartOf\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#website\" },\n      \"inLanguage\": \"lv\",\n      \"about\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#pain-relief-indication\" }\n      ]\n    },\n    \/* 1. ZIN\u0100TNISKAIS RAKSTS *\/\n    {\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/lv\/hipertermija-qol-sapju-kontrole\/#article\",\n      \"headline\": \"Hipertermijas modalit\u0101tes ietekme uz dz\u012bves kvalit\u0101ti (QoL): s\u0101pju mazin\u0101\u0161ana un funkcion\u0101lie ieguvumi\",\n      \"author\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-veronica-iatan\/\" },\n      \"editor\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/cristian-gologan\/\" },\n      \"publisher\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"keywords\": [\"dz\u012bves kvalit\u0101te\", \"s\u0101pju p\u0101rvald\u012bba\", \"A1 l\u012bme\u0146a pier\u0101d\u012bjumi\", \"paliat\u012bv\u0101 apr\u016bpe\", \"EORTC QLQ-C30\"],\n      \"abstract\": \"III f\u0101zes RCT p\u0113t\u012bjumu apkopojums, kas pier\u0101da, ka lokore\u0123ion\u0101l\u0101 RF hipertermija iev\u0113rojami palielina piln\u012bgu s\u0101pju reakciju (CR) kaulu metast\u0101\u017eu gad\u012bjum\u0101 un uzlabo fizisk\u0101s un emocion\u0101l\u0101s funkcion\u0113\u0161anas r\u0101d\u012bt\u0101jus.\",\n      \"mentions\": [\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-chi\" },\n        { \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sahinbas\" }\n      ]\n    },\n    \/* 2. KL\u012aNISKAIS P\u0112T\u012aJUMS - CHI MS ET AL. *\/\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-chi\",\n      \"name\": \"III f\u0101zes RCT: RT pret RT + hipertermija s\u0101p\u012bgu kaulu metast\u0101\u017eu \u0101rst\u0113\u0161anai\",\n      \"studyDesign\": \"Randomized Controlled Trial\",\n      \"outcome\": \"Piln\u012bgas s\u0101pju mazin\u0101\u0161an\u0101s r\u0101d\u012bt\u0101js (CR) 3 m\u0113ne\u0161u laik\u0101 uzlaboj\u0101s no 7,1% (tikai RT) uz 37,9% (RT + hipertermija).\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/29066122\/\"\n    },\n    \/* 3. KL\u012aNISKAIS P\u0112T\u012aJUMS - SAHINBAS\/FAGHIHI ET AL. *\/\n    {\n      \"@type\": \"MedicalStudy\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#studiu-sahinbas\",\n      \"name\": \"III f\u0101zes kl\u012bniskais p\u0113t\u012bjums: term\u0101l\u0101 terapija pret EBRT tikai kaulu metast\u0101\u017eu gad\u012bjum\u0101\",\n      \"studyDesign\": \"Randomized Controlled Trial\",\n      \"outcome\": \"CR r\u0101d\u012bt\u0101js 2 m\u0113ne\u0161u laik\u0101: 47,4% (kombin\u0113t\u0101 terapija) pret 5,3% (tikai staru terapija). Vid\u0113jais laiks l\u012bdz s\u0101pju mazin\u0101\u0161anai: 10 dienas.\",\n      \"url\": \"https:\/\/pubmed.ncbi.nlm.nih.gov\/38460451\/\"\n    },\n    \/* 4. IER\u012aCE - HYDEEP 600 WM *\/\n    {\n      \"@type\": [\"Product\", \"MedicalDevice\"],\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#hydeep-600wm\",\n      \"name\": \"Andromedic HyDeep 600 WM\",\n      \"sku\": \"HYDEEP-600WM-QOL-LV\",\n      \"brand\": { \"@type\": \"Brand\", \"name\": \"Andromedic\" },\n      \"image\": \"https:\/\/andromedichyperthermia.com\/wp-content\/uploads\/2025\/07\/advanced-modulated-RF-hyperthermia-device-Andromedic-HY-DEEP-600WM-local-oncologic-hyperthermia.jpg\",\n      \"description\": \"Sist\u0113ma\/dispozit\u012bvs lok\u0101lai dzi\u013cai hipertermijai. HyDeep 600 WM ir uzlabota onkolo\u0123isk\u0101 hipertermijas ier\u012bce, kas izmanto modul\u0113tu 13.56 MHz RF frekvenci, lai uzlabotu QoL un mazin\u0101tu onkolo\u0123isk\u0101s s\u0101pes.\",\n      \"manufacturer\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#organization\" },\n      \"aggregateRating\": {\n        \"@type\": \"AggregateRating\",\n        \"ratingValue\": \"4.9\",\n        \"reviewCount\": \"40\",\n        \"bestRating\": \"5\",\n        \"worstRating\": \"4\"\n      },\n      \"offers\": {\n        \"@type\": \"Offer\",\n        \"url\": \"https:\/\/andromedichyperthermia.com\/contact\/\",\n        \"price\": \"0\",\n        \"priceCurrency\": \"EUR\",\n        \"availability\": \"https:\/\/schema.org\/InStock\"\n      }\n    },\n    \/* 5. MEDIC\u012aNISK\u0100 INDIK\u0100CIJA *\/\n    {\n      \"@type\": \"MedicalIndication\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/#pain-relief-indication\",\n      \"name\": \"V\u0113\u017ea s\u0101pju mazin\u0101\u0161ana un noguruma kontrole\",\n      \"description\": \"Adjuvanta hipertermija ir indic\u0113ta simptomu kontrolei, saglab\u0101jot fizisko un emocion\u0101lo funkcion\u0113\u0161anu gan paliat\u012bvaj\u0101, gan kurat\u012bvaj\u0101 apr\u016bp\u0113.\",\n      \"guideline\": \"A1 l\u012bme\u0146a pier\u0101d\u012bjumi (Chi MS et al. 2017, Sahinbas 2024)\"\n    },\n    \/* 6. PERSONAS *\/\n    {\n      \"@type\": \"Physician\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/hyperthermia-doctor-veronica-iatan\/\",\n      \"name\": \"Dr. Veronica Iatan\",\n      \"jobTitle\": \"SRHO l\u012bdzdibin\u0101t\u0101ja, medic\u012bnas eksperte\",\n      \"affiliation\": { \"@id\": \"https:\/\/andromedichyperthermia.com\/#srho\" }\n    },\n    {\n      \"@type\": \"Person\",\n      \"@id\": \"https:\/\/andromedichyperthermia.com\/cristian-gologan\/\",\n      \"name\": \"Cristian Gologan\",\n      \"jobTitle\": \"Premium Wellness Distrib SRL CEO, SRHO izpilddirektors un l\u012bdzdibin\u0101t\u0101js\"\n    }\n  ]\n}\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autorit\u0101te un ekspert\u012bze (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autori: <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/lv\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, MD, un <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">, Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermijas ietekme uz dz\u012bves kvalit\u0101ti (QoL): s\u0101pju mazin\u0101\u0161ana, noguruma samazin\u0101\u0161ana un adjuvanti imunolo\u0123iskie ieguvumi<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">M\u016bsdienu onkolo\u0123ij\u0101 v\u0113\u017ea p\u0101rvald\u012bbas m\u0113r\u0137is ir optim\u0101ls l\u012bdzsvars starp <a href=\"https:\/\/andromedichyperthermia.com\/lv\/hipertermija-veza-pacientu-dzivildze\/\">dz\u012bvildzi (OS\/DFS)<\/a> un <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*dz\u012bves kvalit\u0101ti (QoL)*.<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hipertermija (HT) ir unik\u0101la adjuvanta modalit\u0101te, kas ar noz\u012bm\u012bgiem kl\u012bniskajiem p\u0113t\u012bjumiem (<\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/lv\/hipertermijas-iii-fazes-petijumu\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">III f\u0101zes RCT<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">) ir pier\u0101d\u012bjusi, ka t\u0101 uzlabo QoL vair\u0101kos l\u012bme\u0146os: simptomu kontrol\u0113, visp\u0101r\u0113j\u0101 funkcion\u0101laj\u0101 st\u0101vokl\u012b un nodro\u0161ina izcilu dro\u0161\u012bbas profilu.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. Galvenais paliat\u012bvais ieguvums: s\u0101pju kontrole (A1 l\u012bme\u0146a pier\u0101d\u012bjumi no III f\u0101zes kl\u012bniskajiem p\u0113t\u012bjumiem)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metast\u0101tiskas kaulu s\u0101pes pasliktina QoL. Lokore\u0123ion\u0101l\u0101 RF hipertermija kombin\u0101cij\u0101 ar staru terapiju (RT) nodro\u0161ina lab\u0101ku paliat\u012bvo kontroli saska\u0146\u0101 ar <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Chi MS et al. (2017) public\u0113to III f\u0101zes p\u0113t\u012bjumu<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> [1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL indikators\/S\u0101pju uzlabo\u0161an\u0101s<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (HT)<\/span><\/span><\/th>\n<th>Ietekme uz QoL<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pilnas atbildes reakcijas r\u0101d\u012bt\u0101js (CR) p\u0113c 3 m\u0113ne\u0161iem<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (s\u0101pju r\u0101d\u012bt\u0101js nulle)<\/span><\/span><\/td>\n<td>*7,1 %*<\/td>\n<td>*37,9 %*<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">*par 533% palielin\u0101ta* iesp\u0113ja piln\u012bb\u0101 atbr\u012bvoties no s\u0101p\u0113m.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">S\u0101pju mazin\u0101\u0161anas ilgums<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u0101na: *55 dienas\/7,9 ned\u0113\u013cas*<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u0101na: *Nav sasniegta p\u0113c 24 ned\u0113\u013c\u0101m*<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Atvieglojuma ilgums *tr\u012bsk\u0101r\u0161ojas*, samazinot atkar\u012bbu no prets\u0101pju l\u012bdzek\u013ciem.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024. gad\u0101 <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Sahinbas un kol\u0113\u0123i public\u0113ja III f\u0101zes p\u0113t\u012bjumu<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> par kaulu metast\u0101\u017eu s\u0101p\u0113m, galvenok\u0101rt no kr\u016bts un prostatas v\u0113\u017ea, izmantojot WBHT wIRA hipertermiju papildus RT [2].<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Balstoties uz \u0161o p\u0113t\u012bjumu, tikai staru terapijas (RT) grup\u0101 tika nov\u0113rotas visintens\u012bv\u0101k\u0101s s\u0101pes. P\u0113t\u012bjums tika pabeigts p\u0113c 61 pacienta iek\u013cau\u0161anas. Galu gal\u0101 CR r\u0101d\u012bt\u0101js RT + WBH grup\u0101 uzr\u0101d\u012bja visb\u016btisk\u0101ko at\u0161\u0137ir\u012bbu sal\u012bdzin\u0101jum\u0101 ar tikai RT grupu \u2013 attiec\u012bgi 47,4% pret 5,3% divu m\u0113ne\u0161u laik\u0101 p\u0113c \u0101rst\u0113\u0161anas (P v\u0113rt\u012bba &lt; 0,05). Laiks l\u012bdz piln\u012bgai s\u0101pju mazin\u0101\u0161anai RT + WBH grup\u0101 bija 10 dienas, savuk\u0101rt tikai RT grup\u0101 m\u0113r\u0137is netika sasniegts. S\u0101pju progres\u0113\u0161ana vai slim\u012bbas stabilit\u0101te tika nov\u0113rota pusei RT grupas pacientu 4 ned\u0113\u013cu laik\u0101 p\u0113c \u0101rst\u0113\u0161anas, turpretim RT + WBHT pacientiem \u0161is r\u0101d\u012bt\u0101js divu m\u0113ne\u0161u laik\u0101 p\u0113c proced\u016br\u0101m bija tuvu nullei.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Secin\u0101jumi: <\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH kombin\u0101cij\u0101 ar RT uzr\u0101d\u012bja iev\u0113rojamu s\u0101pju mazin\u0101\u0161an\u0101s pieaugumu un \u012bs\u0101ku reakcijas laiku sal\u012bdzin\u0101jum\u0101 ar tikai RT pacientiem ar metast\u0101tiskiem kaulu boj\u0101jumiem.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL indikators\/S\u0101pju uzlabo\u0161an\u0101s<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT monoterapija<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hipertermija (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Ietekme uz QoL<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Pilnas atbildes reakcijas r\u0101d\u012bt\u0101js (CR) p\u0113c 2 m\u0113ne\u0161iem<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (s\u0101pju r\u0101d\u012bt\u0101js nulle)<\/span><\/span><\/td>\n<td>*5,3 %*<\/td>\n<td>*47,4 %*<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894% pieaugums<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * iesp\u0113jai piln\u012bb\u0101 nov\u0113rst s\u0101pes.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Laiks l\u012bdz piln\u012bgai s\u0101pju mazin\u0101\u0161anai<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">netika sasniegts<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dienas<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">&#8220;b\u016btisks un \u0101trs&#8221;<\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"> ieguvums<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">S\u0101pju mazin\u0101\u0161anas ilgums <\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u0101na: *28 dienas\/4 ned\u0113\u013cas* pusei pacientu<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Medi\u0101na: *Nav sasniegta p\u0113c 24 ned\u0113\u013c\u0101m*<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Atvieglojuma ilgums * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">palielin\u0101s se\u0161k\u0101rt\u012bgi<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, samazinot atkar\u012bbu no prets\u0101pju l\u012bdzek\u013ciem.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Funkcion\u0101l\u0101 st\u0101vok\u013ca uzlabo\u0161ana un noguruma mazin\u0101\u0161ana<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT labv\u0113l\u012bg\u0101 ietekme uz QoL ir tie\u0161i izm\u0113r\u0101ma, izmantojot standartiz\u0113tas anketas (EORTC QLQ-C30), kas uzr\u0101da visp\u0101r\u0113j\u0101 st\u0101vok\u013ca uzlabo\u0161anos (fizisk\u0101 funkcija, nogurums un trauksme):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Iev\u0113rojami uzlabota QoL (modul\u0113t\u0101 RF hipertermija mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Randomiz\u0113ts kl\u012bniskais p\u0113t\u012bjums par modul\u0113to RF hipertermiju (mEHT) dzemdes kakla v\u0113\u017ea (CCC) gad\u012bjum\u0101 uzr\u0101d\u012bja *iev\u0113rojamu ilgtermi\u0146a QoL r\u0101d\u012bt\u0101ju uzlabo\u0161anos*, pacientiem zi\u0146ojot par lab\u0101kiem rezult\u0101tiem *fizisk\u0101s un emocion\u0101l\u0101s funkcion\u0113\u0161anas* skal\u0101s. [3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Noguruma kontrole un imunomodul\u0101cija:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Visa \u0137erme\u0146a hipertermija (WBHT) un HT kopum\u0101 pozit\u012bvi ietekm\u0113 *hronisk\u0101 noguruma sindromu (CRF)*, modul\u0113jot pro-iekaisuma citok\u012bnus (IL-6, TNF-alfa). HT pal\u012bdz uztur\u0113t un uzlabot rezult\u0101tus *fizisk\u0101s un emocion\u0101l\u0101s funkcion\u0113\u0161anas* skal\u0101s ilgtermi\u0146\u0101. [4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u0100tra emocion\u0101l\u0101 atvese\u013co\u0161an\u0101s (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> P\u0113c liel\u0101m \u0137irur\u0123isk\u0101m proced\u016br\u0101m, kas ietver HT (HIPEC), emocion\u0101l\u0101 QoL m\u0113dz *\u0101tri uzlaboties*, s\u0101kot jau no *3 m\u0113ne\u0161iem* p\u0113c oper\u0101cijas, bie\u017ei p\u0101rsniedzot s\u0101kotn\u0113jo l\u012bmeni. [5]<\/span><\/span><\/li>\n<\/ul>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Ilgtermi\u0146a QoL ieguvumu nostiprin\u0101\u0161ana<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Re\u0101l\u0101s pasaules dati un kl\u012bniskie p\u0113t\u012bjumi progres\u0113jo\u0161a v\u0113\u017ea gad\u012bjumos apstiprina hipertermijas lomu ilgtermi\u0146a QoL stabiliz\u0113\u0161an\u0101 un uzlabo\u0161an\u0101:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kurat\u012bv\u0101 ietekme p\u0113c 12 m\u0113ne\u0161iem:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Pla\u0161a to pacientu anal\u012bze, kuri \u0101rst\u0113ti ar kurat\u012bvu m\u0113r\u0137i (RCT + HT), uzr\u0101d\u012bja b\u016btisku uzlabojumu 12 m\u0113ne\u0161u period\u0101 QoL apak\u0161skal\u0101s, kas nov\u0113rt\u0113 emocion\u0101lo funkciju, soci\u0101lo funkciju un bezmiegu (SL), sal\u012bdzin\u0101jum\u0101 ar EORTC onkolo\u0123ijas atsauces popul\u0101ciju. [10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Paliat\u012bvie ieguvumi:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Paliat\u012bv\u0101 kontekst\u0101 HT pievieno\u0161ana standarta \u0101rst\u0113\u0161anai izrais\u012bja kl\u012bniski noz\u012bm\u012bgu s\u0101pju (PA) uzlabo\u0161anos un finansi\u0101lo gr\u016bt\u012bbu (FI) samazin\u0101\u0161anos 3 m\u0113ne\u0161us p\u0113c \u0101rst\u0113\u0161anas, veicinot lab\u0101ku visp\u0101r\u0113jo pacienta st\u0101vokli. [10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Uzlabota QoL progres\u0113jo\u0161as slim\u012bbas gad\u012bjum\u0101 (kolorekt\u0101lais v\u0113zis):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> P\u0113t\u012bjum\u0101, kur\u0101 v\u0113rt\u0113ta \u0137\u012bmijterapijas papildin\u0101\u0161ana ar augstas frekvences hipertermiju pacientiem ar vid\u0113jas un progres\u0113jo\u0161as stadijas kolorekt\u0101lo v\u0113zi, grupai, kas sa\u0146\u0113ma kombin\u0113to terapiju, p\u0113c 4 \u0101rst\u0113\u0161anas cikliem bija iev\u0113rojami augst\u0101ki (uzlaboti) QoL r\u0101d\u012bt\u0101ji, pier\u0101dot, ka HT efekt\u012bvi uzlabo QoL papildus terapeitiskajam efektam, vienlaikus saglab\u0101jot augstu dro\u0161\u012bbu. [11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuvanti biolo\u0123iskie ieguvumi un augst\u0101ks terapeitiskais indekss<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maksim\u0101li palielina \u0101rst\u0113\u0161anas efektivit\u0101ti, b\u016btiski nepalielinot smagas toksicit\u0101tes risku (3.-4. pak\u0101pe), t\u0101d\u0113j\u0101di uzturot augstu terapeitisko indeksu:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Valid\u0113ta dro\u0161\u012bba (III f\u0101zes kl\u012bniskie p\u0113t\u012bjumi):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Dzemdes kakla v\u0113\u017ea meta-anal\u012bzes uzr\u0101da *neb\u016btisku at\u0161\u0137ir\u012bbu* ak\u016bt\u0101 vai v\u0113l\u012bn\u0101 toksicit\u0101t\u0113 (RR toksicit\u0101te 1.01) [6]. Dro\u0161\u012bbas profils tiek saglab\u0101ts ar\u012b taisn\u0101s zarnas v\u0113\u017ea [7] un aizku\u0146\u0123a dziedzera v\u0113\u017ea p\u0113t\u012bjumos. [8]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Org\u0101nu saglab\u0101\u0161ana:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Taisn\u0101s zarnas v\u0113\u017ea gad\u012bjum\u0101 HT pievieno\u0161ana neoadjuvantai \u0137\u012bmijstaru terapijai palielina 5 gadu dz\u012bvildzi bez kolostomas (CFS) no 69,0% uz *87,7%*, kas ir b\u016btisks funkcion\u0101ls ieguvums QoL. [7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abskop\u0101lais (vakc\u012bnai l\u012bdz\u012bgs) efekts:<\/strong> HT ierosina imunog\u0113nu \u0161\u016bnu n\u0101vi, atbr\u012bvojot *siltuma \u0161oka olbaltumvielas (HSP)*, kas aktiviz\u0113 citotoksisk\u0101s CD8+ T \u0161\u016bnas. \u0160is sist\u0113miskais imunolo\u0123iskais solis veicina atliku\u0161\u0101s slim\u012bbas kontroli un ir b\u016btisks adjuvants ieguvums. [9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Secin\u0101jums: Uz pacientu orient\u0113ta terapija<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hipertermijas integr\u0113\u0161ana onkolo\u0123ijas protokol\u0101 ir uz pier\u0101d\u012bjumiem balst\u012bta strat\u0113\u0123ija, kas ne tikai uzlabo dz\u012bvildzi, bet ar\u012b nodro\u0161ina stabilu simptomu kontroli un uztur dz\u012bves kvalit\u0101ti. S\u0101pju mazin\u0101\u0161ana, noguruma kontrole un izcilais dro\u0161\u012bbas profils padara HT par b\u016btisku elementu holistisk\u0101 onkolo\u0123isk\u0101 pacienta apr\u016bp\u0113.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Aicin\u0101m konsult\u0113ties ar m\u016bsu ekspertiem, lai integr\u0113tu hipertermiju j\u016bsu protokol\u0101 ar m\u0113r\u0137i maksim\u0101li palielin\u0101t gan efektivit\u0101ti, gan dz\u012bves kvalit\u0101ti.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT Assurance:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> \u0160is saturs ir balst\u012bts uz public\u0113tiem datiem no III f\u0101zes randomiz\u0113tiem un perspekt\u012bviem kl\u012bniskajiem p\u0113t\u012bjumiem, izmantojot standarta dz\u012bves kvalit\u0101tes m\u0113r\u012b\u0161anas r\u012bkus (EORTC QLQ-C30). Pilnas atsauces ir integr\u0113tas ar tie\u0161\u0101m sait\u0113m uz avotu publik\u0101cij\u0101m.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Atsauces:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. | Ostberg, K., et al. (2008). Clinical Rheumatology<\/li>\n<li>\n<p class=\"title\"><span class=\"author_name_wrap\"><span class=\"author_name\">Ryan B. Morgan<\/span><sup>1<\/sup><\/span>, <span class=\"author_name_wrap\"><span class=\"author_name\">Sandy Tun<\/span><sup>2<\/sup><\/span>, <span class=\"author_name_wrap\"><span class=\"author_name\">Oliver S. Eng<\/span><sup>1<\/sup><\/span>Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review<\/p>\n<\/li>\n<li>\n<p class=\"title\">Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/p>\n<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S. <i>et al.<\/i> Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus. <i>Strahlenther Onkol<\/i> <b>195<\/b>, 607\u2013614 (2019). https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy <i>vs<\/i> chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. (2020). Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Frontiers in Oncology.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autorit\u0101te un ekspert\u012bze (EEAT): Autori: Dr. Veronica Iatan, MD, un Cristian Gologan M.Sc, Andromedichyperthermia Hipertermijas ietekme uz dz\u012bves kvalit\u0101ti (QoL): s\u0101pju mazin\u0101\u0161ana, noguruma samazin\u0101\u0161ana un adjuvanti imunolo\u0123iskie ieguvumi M\u016bsdienu onkolo\u0123ij\u0101 v\u0113\u017ea p\u0101rvald\u012bbas m\u0113r\u0137is ir optim\u0101ls l\u012bdzsvars starp dz\u012bvildzi (OS\/DFS) un *dz\u012bves kvalit\u0101ti (QoL)*. Hipertermija (HT) ir unik\u0101la adjuvanta modalit\u0101te, kas ar noz\u012bm\u012bgiem kl\u012bniskajiem p\u0113t\u012bjumiem (III&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[172,951,37],"tags":[952,953,954,381,335,955,956,957,958],"class_list":["post-11445","post","type-post","status-publish","format-standard","hentry","category-news-lv","category-studii-clinice-lv","category-uncategorized-lv","tag-calitatea-vietii-lv","tag-durere-lv","tag-hipertermie-oncologica-lv","tag-hipertermija-lv","tag-oncology-lv","tag-pain-lv","tag-phase-iii-trial-lv","tag-qol-lv","tag-studii-faza-iii-lv"],"gutentor_comment":0,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/posts\/11445","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/comments?post=11445"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/posts\/11445\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/media?parent=11445"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/categories?post=11445"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/lv\/wp-json\/wp\/v2\/tags?post=11445"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}